These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34811370)

  • 1. A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients.
    Jenum S; Tonby K; Rueegg CS; Rühwald M; Kristiansen MP; Bang P; Olsen IC; Sellæg K; Røstad K; Mustafa T; Taskén K; Kvale D; Mortensen R; Dyrhol-Riise AM
    Nat Commun; 2021 Nov; 12(1):6774. PubMed ID: 34811370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.
    Luabeya AK; Kagina BM; Tameris MD; Geldenhuys H; Hoff ST; Shi Z; Kromann I; Hatherill M; Mahomed H; Hanekom WA; Andersen P; Scriba TJ; ; Schoeman E; Krohn C; Day CL; Africa H; Makhethe L; Smit E; Brown Y; Suliman S; Hughes EJ; Bang P; Snowden MA; McClain B; Hussey GD
    Vaccine; 2015 Aug; 33(33):4130-40. PubMed ID: 26095509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole blood RNA signatures in tuberculosis patients receiving H56:IC31 vaccine as adjunctive therapy.
    Alonso-Rodríguez N; Vianello E; van Veen S; Jenum S; Tonby K; van Riessen R; Lai X; Mortensen R; Ottenhoff THM; Dyrhol-Riise AM
    Front Immunol; 2024; 15():1350593. PubMed ID: 38433842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial.
    Suliman S; Luabeya AKK; Geldenhuys H; Tameris M; Hoff ST; Shi Z; Tait D; Kromann I; Ruhwald M; Rutkowski KT; Shepherd B; Hokey D; Ginsberg AM; Hanekom WA; Andersen P; Scriba TJ; Hatherill M;
    Am J Respir Crit Care Med; 2019 Jan; 199(2):220-231. PubMed ID: 30092143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in
    Bekker LG; Dintwe O; Fiore-Gartland A; Middelkoop K; Hutter J; Williams A; Randhawa AK; Ruhwald M; Kromann I; Andersen PL; DiazGranados CA; Rutkowski KT; Tait D; Miner MD; Andersen-Nissen E; De Rosa SC; Seaton KE; Tomaras GD; McElrath MJ; Ginsberg A; Kublin JG;
    EClinicalMedicine; 2020 Apr; 21():100313. PubMed ID: 32382714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Immunogenicity of the H56:IC31 Tuberculosis Vaccine Candidate in Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis: A Phase 1 Randomized Trial.
    Tait D; Diacon A; Borges ÁH; van Brakel E; Hokey D; Rutkowski KT; Hunt DJ; Russell M; Andersen PL; Kromann I; Ruhwald M; Churchyard G; Dawson R
    J Infect Dis; 2024 Nov; 230(5):1262-1270. PubMed ID: 38557639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H1:IC31 vaccination is safe and induces long-lived TNF-α
    Mearns H; Geldenhuys HD; Kagina BM; Musvosvi M; Little F; Ratangee F; Mahomed H; Hanekom WA; Hoff ST; Ruhwald M; Kromann I; Bang P; Hatherill M; Andersen P; Scriba TJ;
    Vaccine; 2017 Jan; 35(1):132-141. PubMed ID: 27866772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials.
    Norrby M; Vesikari T; Lindqvist L; Maeurer M; Ahmed R; Mahdavifar S; Bennett S; McClain JB; Shepherd BM; Li D; Hokey DA; Kromann I; Hoff ST; Andersen P; de Visser AW; Joosten SA; Ottenhoff THM; Andersson J; Brighenti S
    Vaccine; 2017 Mar; 35(12):1652-1661. PubMed ID: 28216183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The TB vaccine H56+IC31 dose-response curve is peaked not saturating: Data generation for new mathematical modelling methods to inform vaccine dose decisions.
    Rhodes SJ; Zelmer A; Knight GM; Prabowo SA; Stockdale L; Evans TG; Lindenstrøm T; White RG; Fletcher H
    Vaccine; 2016 Dec; 34(50):6285-6291. PubMed ID: 27816373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.
    Geldenhuys H; Mearns H; Miles DJ; Tameris M; Hokey D; Shi Z; Bennett S; Andersen P; Kromann I; Hoff ST; Hanekom WA; Mahomed H; Hatherill M; Scriba TJ; ; van Rooyen M; Bruce McClain J; Ryall R; de Bruyn G;
    Vaccine; 2015 Jul; 33(30):3592-9. PubMed ID: 26048780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conservation in gene encoding Mycobacterium tuberculosis antigen Rv2660 and a high predicted population coverage of H56 multistage vaccine in South Africa.
    Perez-Martinez AP; Ong E; Zhang L; Marrs CF; He Y; Yang Z
    Infect Genet Evol; 2017 Nov; 55():244-250. PubMed ID: 28941991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection.
    Lin PL; Dietrich J; Tan E; Abalos RM; Burgos J; Bigbee C; Bigbee M; Milk L; Gideon HP; Rodgers M; Cochran C; Guinn KM; Sherman DR; Klein E; Janssen C; Flynn JL; Andersen P
    J Clin Invest; 2012 Jan; 122(1):303-14. PubMed ID: 22133873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrapulmonary (i.pulmon.) Pull Immunization With the Tuberculosis Subunit Vaccine Candidate H56/CAF01 After Intramuscular (i.m.) Priming Elicits a Distinct Innate Myeloid Response and Activation of Antigen-Presenting Cells Than i.m. or i.pulmon. Prime Immunization Alone.
    Thakur A; Pinto FE; Hansen HS; Andersen P; Christensen D; Janfelt C; Foged C
    Front Immunol; 2020; 11():803. PubMed ID: 32457748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.
    Nemes E; Geldenhuys H; Rozot V; Rutkowski KT; Ratangee F; Bilek N; Mabwe S; Makhethe L; Erasmus M; Toefy A; Mulenga H; Hanekom WA; Self SG; Bekker LG; Ryall R; Gurunathan S; DiazGranados CA; Andersen P; Kromann I; Evans T; Ellis RD; Landry B; Hokey DA; Hopkins R; Ginsberg AM; Scriba TJ; Hatherill M;
    N Engl J Med; 2018 Jul; 379(2):138-149. PubMed ID: 29996082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area.
    Hussein J; Zewdie M; Yamuah L; Bedru A; Abebe M; Dagnew AF; Chanyalew M; Yohannes AG; Ahmed J; Engers H; Doherty TM; Bang P; Kromann I; Hoff ST; Aseffa A
    Trials; 2018 Jan; 19(1):24. PubMed ID: 29321075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Cyclooxygenase 2 Inhibitor Etoricoxib as Adjunctive Therapy in Tuberculosis Impairs Macrophage Control of Mycobacterial Growth.
    Nore KG; Louet C; Bugge M; Gidon A; Jørgensen MJ; Jenum S; Dyrhol-Riise AM; Tonby K; Flo TH
    J Infect Dis; 2024 Mar; 229(3):888-897. PubMed ID: 37721470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4+ T Cells.
    Lenz N; Schindler T; Kagina BM; Zhang JD; Lukindo T; Mpina M; Bang P; Kromann I; Hoff ST; Andersen P; Reither K; Churchyard GJ; Certa U; Daubenberger CA
    Clin Vaccine Immunol; 2015 Jul; 22(7):688-96. PubMed ID: 25924764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making.
    Rhodes SJ; Guedj J; Fletcher HA; Lindenstrøm T; Scriba TJ; Evans TG; Knight GM; White RG
    NPJ Vaccines; 2018; 3():36. PubMed ID: 30245860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating Non-human Primate, Human, and Mathematical Studies to Determine the Influence of BCG Timing on H56 Vaccine Outcomes.
    Joslyn LR; Pienaar E; DiFazio RM; Suliman S; Kagina BM; Flynn JL; Scriba TJ; Linderman JJ; Kirschner DE
    Front Microbiol; 2018; 9():1734. PubMed ID: 30177914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll like-receptor agonist Pam
    Kennerknecht K; Noschka R; Löffler F; Wehrstedt S; Pedersen GK; Mayer D; Grieshober M; Christensen D; Stenger S
    Med Microbiol Immunol; 2020 Apr; 209(2):163-176. PubMed ID: 32020284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.